IDH-mutant glioma
Trial arms side by side.
One row is one arm. A blank cell is n/r. A hazard ratio appears only when the source states it. Weeks stay weeks, and a patient count stays a count.
ClassNone selected
No arms selected. Choose a drug, an arm, or a preset.
Each arm uses its closest stored timepoint inside the window.
value
Source: Cited trial source for each arm. The timepoint in the table is the one this chart used.
No selected arm has this endpoint inside the time window.
Show as table
| Arm | Trial | Phase | Population | n | Comparator | Timepoint | Estimand | Assessor | Value |
|---|
Not shown
Every selected arm is drawn.
7 of 9 arms with a reported figure. Choose arms to narrow the chart.
Vorasidenib 40 mg. objective response rate, extended follow-up: 20.8%, ASCO 2026, preliminary
Vorasidenib Phase 1 doses. objective response rate: 18%, Phase 1
Safusidenib (AB-218, DS-1001) 250 mg. confirmed objective response rate: 51.9%, median follow-up 38.8 months
Olutasidenib 150 mg. objective response rate: 8%, 2 of 25
A note on interpreting comparisons: this page lines up results from different trials so the broader evidence is visible. Treat a gap between arms as context. A randomized trial that assigns the treatments in the same study is the strongest comparison.